Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?

Leukemia Research

Volumn 33, Issue 11, 2009, Pages 1450-1451

  Breccia, Massimo ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chronic myeloid leukemia; Imatinib; Prognostic factors

Indexed keywords

ABELSON KINASE; ADAPTOR PROTEIN; BCR ABL PROTEIN; IMATINIB; ONCOPROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; WT1 PROTEIN;

ANEMIA; BINDING COMPETITION; CANCER GROWTH; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; EDITORIAL; ERYTHROCYTE VOLUME; FUSION GENE; GENE EXPRESSION; GENOMICS; HEMATOPOIETIC STEM CELL; HUMAN; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; RISK ASSESSMENT;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROCYTE INDICES; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PIPERAZINES; PYRIMIDINES; RETROSPECTIVE STUDIES;

EID: 68649112783     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.06.022     Document Type: Editorial

References (15)

1. Faderl S., Talpaz M., Estrov Z., and Kantarjian H. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 131 (1999) 207-219
2. Goldman J.M., and Melo J.V. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 349 (2003) 1451-1464
3. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 112 (2008) 4808-4817
4. Sattler M., and Griffin J.D. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 40 (2003) 4-10
5. Baccarani M., Saglio G., Goldman J., Hochhaus A., Simonsson B., Appelbaum F., et al. European Leukemia Net. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (2006) 1809-1820
6. Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New Engl J Med 349 (2003) 1423-1432
7. Simonsson B, on behalf of the IRIS study group. Beneficial effects of cytogenetic and molecular response on long term outcome in patients with newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP) treated with imatinib: update from the IRIS study. Blood 2005;106:52a
8. Quintas-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myelogenous leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009;Apr 15 [Epub ahead of print].
9. Wang L., Pearson K., Ferguson J.E., and Clark R.E. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 120 (2003) 990-999
10. Merx K., Müller M.C., Kreil S., Lahaye T., Paschka P., Schoch C., et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 16 (2002) 1579-1583
11. Paschka P., Müller M.C., Merx K., Kreil S., Schoch C., Lahaye T., et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia 17 (2003) 1687-1694
12. Hughes T.P., Hochhaus A., Branford S., Muller M.C., Foroni L., Druker B.J., et al. Reduction of BCR-ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on imatinib (IM) at 72 Mo: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in patients (pts) with chronic phase chronic myeloid leukemia (CML-CP). Blood 112 (2008) abstr 334
13. Picard S., Titier K., Etienne G., Teilhet E., Ducint D., Bernard M.A., et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109 (2007) 3496-3499
14. Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon FX. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 2009;Apr 30 [Epub ahead of print].
15. Song M.K., Chung J.S., Seol Y.M., Shin H.J., Choi Y.J., Cho G.J., et al. Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukaemia patients treated with imatinib?. Leuk Res 33 (2009) 1459-1462